Association of JAG1 gene polymorphism with systemic blood pressure in patients with obstructive sleep apnea: a prospective cohort study

Aim To assess the effects of single nucleotide polymorphisms (SNPs) on blood pressure control in patients with obstructive sleep apnea (OSA).

Methods This prospective observational cohort study, conducted between 2004 and 2014, examined the associations of SNPs of JAG1, GUCY1A3-GUCY1B3, SH2B3, and NPR3-C5orf23 genes with systolic and diastolic blood pressure (SBP, DBP) in 1179 adults evaluated for OSA with overnight polysomnography. Genotyping was performed by unlabeled probe melting analysis.

Results The patients were predominantly male (69.6%, mean age 52 ± 11 years, apnea-hypopnea index 34 ± 31 episodes/h). Only JAG1 genotype was associated with SBP and DBP; compared with AA homozygotes, G allele carriers (pooled GG and AG genotype) had significantly higher morning SBP (132 ± 19 vs 129 ± 18 mm Hg; \( P = 0.009 \)) and morning and evening DBP (85 ± 11 vs 83 ± 10 mm Hg, \( P = 0.004 \); 86 ± 10 vs 84 ± 10 mm Hg, \( P = 0.012 \), respectively); the differences remained significant after the correction for multiple SNPs testing. In multivariate analyses, oxygen desaturation index and JAG1 genotype independently predicted morning SBP (\( P = 0.001 \), \( P = 0.003 \), respectively) and DBP (\( P < 0.001 \), \( P = 0.005 \), respectively), and evening SBP (\( P = 0.019 \), \( P = 0.048 \), respectively) and DBP (\( P = 0.018 \), \( P = 0.018 \), respectively).

Conclusion This is the first replication study of the SNPs recently linked to arterial hypertension in general population by genome-wide association studies. Our findings suggest that JAG1 genotype is related to blood pressure control in OSA. G allele was associated with higher morning and evening SBP and DBP.
Blood pressure is a multifactorial trait. International guidelines for the management of arterial hypertension recognize obstructive sleep apnea (OSA) as the most prevalent cause of secondary hypertension (1) and the most important factor in drug-resistant hypertension (2). Increases in OSA severity are directly linked to increases in systolic and diastolic blood pressure (SBP, DBP) and to the odds for the development of arterial hypertension (3).

Another factor that profoundly affects blood pressure control is heredity. Approximate heritability of blood pressure ranges between 30%-50% (4). The material basis for this heritability is coded in two types of genetic variants: a) major-effect genetic variants that are responsible for rare familial hypertension syndromes, contributing to blood pressure increases at the level of several millimeters of mercury (mmHg), b) small-effect genetic variants that independently influence blood pressure at the level of up to 1 mm Hg for SBP and of up to 0.5 mm Hg for DBP (4,5). Small-effect genetic variants include repetition mutations, inversions, and, most importantly, single nucleotide polymorphisms (SNPs), which may occur throughout the genome in coding, non-coding, and regulator parts of genes. Several genome-wide association studies (GWASs) revealed signals in particular genetic loci linked to blood pressure control in general population and identified over 100 SNPs associated with either blood pressure increase or arterial hypertension (6). Nevertheless, the identified loci linked to blood pressure were seldom localized inside or close to regions with known function in blood pressure control. In contrast, most of the SNPs identified by GWASs were located next to genes with pleiotropic effects, such as prenatal cardiovascular development, inter- and intracellular signaling, hematopoiesis, or metabolism of natriuretic peptides (4). Moreover, several of the newly identified SNPs linked to blood pressure control were in previous studies associated with the increased risk of coronary artery disease (7).

Although GWASs recognized the effects of certain SNPs on blood pressure regulation in the general population (5-7), there is a paucity of data about the potential effects of these SNPs in patients with pre-existing medical conditions known to modify blood pressure control. The present study aimed to evaluate the associations between blood pressure and selected gene polymorphisms with GWAS-recognized effects on blood pressure control ([rs3184504 of the SH2B3 gene, rs1327235 of the JAG1 gene, rs13139571 of the GUCY1A3-1B3 gene, and rs1173771 of the NPR3c5orf23 gene]) in individuals referred to a sleep laboratory for OSA evaluation. The selection of four distinct SNPs was guided by several previous studies that identified the relationships between these polymorphisms and blood pressure, arterial hypertension, and coronary artery disease in general population as summarized by Waken et al (6).

PATIENTS AND METHODS

Patients

In this prospective observational cohort study, 1179 individuals referred to the sleep unit at a tertiary referral university hospital (Department of Respiratory Medicine, L. Pasteur University Hospital, Košice, Slovakia) for a diagnostic sleep study were recruited consecutively between 2004 and 2014. They were all clinically stable adults (age over 18 years) with or without OSA. Exclusion criteria were respiratory failure, arterial hypertension secondary to a disease different from OSA, and any cardiovascular instability including accelerated hypertension. The study was approved by the L. Pasteur University Hospital Ethics Committee, and all patients gave written informed consent.

Sleep assessment

All patients underwent overnight polysomnography (Alice 4 and Alice 5; Respironics Inc., Murrysville, PA, USA), which consisted of electroencephalography (EEG), electrooculography, electromyography, thoracic and abdominal impedance belts, thermistor flowmeter for nasal and oral airflow, microphone for snoring, and pulse oximetry. Records were scored manually following the criteria of the American Academy for Sleep Medicine (AASM) 2007 guidelines and 2012 update (8).

Apnea was defined as a reduction of airflow of ≥90% from the baseline with duration ≥10 s; hypopnea was defined as a reduction in airflow of ≥50% of baseline for ≥10 s, followed by a decrease in oxygen saturation for ≥3%, arousal, or both. Alternatively, hypopnea was identified if reduction of airflow ≥30% from the baseline was present and accompanied with a decrease in saturation ≥4%. Apnea/hypopnea index (AHI) was defined as the total number of apneic and hypopneic events per hour of sleep. Oxygen desaturation index (ODI) was calculated as the number of episodes of reductions in oxygen saturation of ≥3% per hour of sleep, and arousal index was used as a marker of sleep fragmentation characterized as the number of arousals on EEG recording per hour of sleep.
Patients with AHI less than five episodes per hour had no OSA. In patients diagnosed with OSA, its severity was classified based on AASM guidelines, with AHI ≥ 5 and < 15 episodes/h labeled as mild OSA, AHI ≥ 15 and < 30 episodes/h as moderate OSA, and AHI ≥ 30 episodes/h as severe OSA (9).

**Blood pressure measurements**

Blood pressure was measured in a sitting position by using a certified manometric device in the evening, immediately before the montage of polysomnographic leads after at least of 10 minutes of no physical effort (10), and in the morning after awakening before the removal of the leads. Systolic and diastolic blood pressure were measured three times by a trained nurse, and the mean value of the last two measurements was recorded. Manual sphygmomanometer (Welch Allyn type Gold Series DS66 Trigger An- 
edrics, Chicago, IL, USA) with annually certified accuracy of ±2.5% was used for all blood pressure measurements.

**Genotyping**

Peripheral blood samples for leukocyte DNA extraction were collected by a trained nurse by venipuncture of the cubital vein in the morning after diagnostic polysomnography. DNA was extracted with the QIAamp DNA Blood Mini QIAcube Kit according to the manufacturer’s instructions on the QIAcube – robotic workstation for automated purification of DNA, RNA, or proteins (QIAGEN, Hilden, Germany). Four variants of interest were analyzed by high-resolution melting analysis (HRMA) after real-time polymerase chain reaction in the presence of LCGreen Plus dye (BioFire Defense, Salt Lake City, UT, USA) on Eco Real-Time PCR System (Illumina Inc., San Diego, CA, USA). Specifically, SH2B3 rs3184504, JAG1 rs1327235, GUCY1A3 rs13139571, NPR3 rs1173771 polymorphisms were identified by HRMA in the presence of unlabeled probe. The oligonucleotide sequences used for the analyses (Sigma-Aldrich, Haverhill, UK) are shown in Table 1. Genotypes were identified using Eco™ Software 4.1. Genotyping success rate for all examined variants was 100%, and duplicate genotyping concordance was 100% (5 samples for each genotype).

**Statistical analysis**

Normality of the distribution was assessed by Kolmogorov-Smirnov test. The data are presented as mean ± standard deviation (SD). Differences between groups were analyzed using one way ANOVA for parametric variables and ANOVA on ranks for nonparametric variables. Holm-Sidak test was used for post hoc pair-wise comparisons between groups with different OSA severity. Differences in proportions between groups were analyzed with χ² test. A two-tailed P-value of < 0.05 was considered significant for comparisons between groups with different OSA severity. The alleles of the selected SNPs that confer an increase in blood pressure were referenced according to the genome database in the project Ensembli GRCh38 (11). For comparisons between the respective genetic variants for each genotyped polymorphism, the cohort was divided into two groups (a dominant model): the first group comprised the individuals with one or more copy of the risky allele (ie, conferring an increase in blood pressure) and the second group comprised the homozygotes for the non-risky allele. Consequently, after applying the Bonferroni

| Gene (risky/non-risky allele) | Oligonucleotides sequences (Sigma-Aldrich, Haverhill, UK) used in genotyping of variants of interest | Sequence 5′ → 3′ |
|-------------------------------|-------------------------------------------------------------------------------------------------|----------------|
| SH2B3 (T/C)                   | forward-limit AGCAGCTTGCTCCAGCATC                                                             |               |
|                               | reverse-excess TGTTAGGTGTCAGCCATCT                                                            |               |
|                               | probe GAGGTCCGGCGGTCGACAC-Phos                                                               |               |
| JAG1 (G/A)                    | forward-excess CTAACCAACACTTGGCAGACTC                                                       |               |
|                               | reverse-limit CATCATGAAATGTAATCAGACTCCAG                                                    |               |
|                               | probe AAATCCCAGTATGCCCCACCAACAA-Phos                                                         |               |
| GUCY1A3 (C/A)                 | forward-limit ATTCCTTTTCTGCGTCCGCCT                                                        |               |
|                               | reverse-excess GTGAGTATAGACACAATCTTCTCTGAGTTTGC                                             |               |
|                               | probe CTAACATTTTATTTCTGCTGT-Phos                                                             |               |
| NPR3 (G/A)                    | forward-limit CTGATATTTTCTGACACTCC                                                         |               |
|                               | reverse-excess TGGGACACCAACCAACAT                                                           |               |
|                               | probe CTTTGGTGCTTTTGTGATAAGTTTGATG-Phos                                                      |               |
Correction for 4 tested SNPs, a \( P \)-value of <0.0125 was considered significant (\( \alpha = 0.05/4 = 0.0125 \)). Graphic outputs of the blood pressure comparisons between genotype groups were created with SigmaPlot version 8 (SPSS, Chicago, IL, USA) and Microsoft Powerpoint (Redmond, WA, USA). Linear relationships between blood pressure and indices of OSA severity were analyzed by calculating the Pearson correlation coefficient. In multivariate analyses, multiple linear regression models were used with blood pressure as a dependent variable, and age, sex, body mass index (BMI), antihypertensive use, ODI, and genotype as independent variables. Associations in the linear regression models are presented as nominally significant (\( P < 0.05 \)). All analyses were carried out using SPSS, version 14 (IBM, Chicago, IL, USA).

Hardy-Weinberg equilibrium for each genotype was tested using an online calculator (http://www.oege.org/software/hwe-mr-calc.shtml). The genotypes were considered to be distributed as expected under Hardy-Weinberg equilibrium if the calculated \( \chi^2 \) was <3.84 (ie, \( P \) value ≥0.05) (12).

**RESULTS**

**Cohort characteristics**

The study involved 1179 participants (821 or 69.6% men) with mean age 52.0 ± 11.4 years (18 to 81 years; median [interquartile range] of 54.0 [45.0-60.0] years) and mean AHI 34.4 ± 30.9 episodes/h (0.1 to 157.8 episodes/h; median [in-}

| TABLE 2. Demographic characteristics and polysomnographic findings in the study participants** |
|---------------------------------------------------------------|
|                                                                 |
| **Participants (n)**                                          |
| **Entire cohort** | **No OSA** | **Mild OSA** | **Moderate OSA** | **Severe OSA** | **P** |
| 1179            | 202        | 250          | 186             | 541            |
| **Sex**                                           |            |
| male            | 821 (70)   | 101 (50)     | 168 (67)        | 125 (67)       | 427 (79) | <0.001 |
| female          | 358 (30)   | 101 (50)     | 82 (33)         | 63 (31)        | 114 (21) |
| **Age (years)**                                      | 52.0 ± 11.4| 47.2 ± 11.9  | 51.4 ± 11.8     | 52.9 ± 11.3    | 53.9 ± 10.4 | <0.001 |
| **BMI (kg/m²)**                                      | 32.5 ± 6.6 | 28.5 ± 4.8   | 30.2 ± 5.9      | 32.0 ± 5.9     | 35.2 ± 6.5 | <0.001 |
| **Current smoker**                                    | 388 (33)   | 67 (33)      | 76 (30)         | 53 (28)        | 192 (35) | 0.262 |
| **Arterial hypertension**                            | 732 (62)   | 92 (46)      | 120 (48)        | 122 (66)       | 398 (74) | <0.001 |
| **Type 2 diabetes**                                   | 161 (14)   | 7 (3)        | 22 (9)          | 29 (16)        | 103 (19) | <0.001 |
| **CAD**                                              | 198 (17)   | 21 (10)      | 30 (12)         | 35 (19)        | 112 (21) | <0.001 |
| **MI**                                               | 56 (5)     | 5 (2)        | 5 (2)           | 11 (6)         | 35 (6)   | 0.14  |
| **Stroke**                                           | 52 (4)     | 4 (2)        | 6 (2)           | 9 (5)          | 33 (6)   | 0.03  |
| **Antihypertensives**                                 | 680 (58)   | 81 (41)      | 116 (47)        | 115 (63)       | 368 (68) | <0.001 |
| **Alpha blockers**                                    | 97 (8)     | 8 (4)        | 15 (6)          | 17 (9)         | 57 (11)  | 0.015 |
| **Beta blockers**                                     | 333 (29)   | 40 (20)      | 49 (20)         | 55 (30)        | 189 (35) | <0.001 |
| **Calcium channel blockers**                         | 291 (25)   | 33 (17)      | 47 (19)         | 47 (26)        | 164 (31) | <0.001 |
| **Diuretics**                                         | 248 (21)   | 19 (10)      | 33 (13)         | 37 (20)        | 159 (30) | <0.001 |
| **ACEI**                                              | 315 (27)   | 30 (15)      | 52 (21)         | 55 (30)        | 178 (33) | <0.001 |
| **Sartans**                                           | 174 (15)   | 19 (10)      | 27 (11)         | 22 (12)        | 106 (20) | <0.001 |
| **NREM (min)**                                        | 357.3 ± 64.3| 344.3 ± 59.0| 350.5 ± 59.3    | 347.4 ± 61.2   | 368.6 ± 67.7 | <0.001 |
| **S1 NREM (min)**                                     | 58.6 ± 49.6| 49.2 ± 45.5  | 51.1 ± 37.2     | 51.9 ± 39.9    | 67.9 ± 57.1 | <0.001 |
| **S2 NREM (min)**                                     | 249.1 ± 77.8| 237.9 ± 65.5| 239.0 ± 65.5    | 233.7 ± 66.8   | 263.3 ± 87.4 | <0.001 |
| **SWS (min)**                                         | 49.5 ± 35.1| 57.2 ± 35.1  | 60.5 ± 35.2     | 61.7 ± 34.7    | 374 ± 31.2 | <0.001 |
| **REM (min)**                                         | 60.7 ± 34.8| 64.3 ± 36.0  | 69.0 ± 31.4     | 66.9 ± 34.7    | 53.4 ± 34.6 | <0.001 |
| **AHI (episodes/h)**                                  | 34.5 ± 30.9| 2.4 ± 1.5    | 9.6 ± 2.9       | 21.3 ± 4.0     | 62.6 ± 23.4 | <0.001 |
| **ODI (episodes/h)**                                  | 29.5 ± 30.0| 3.2 ± 8.3    | 7.4 ± 7.0       | 16.7 ± 9.7     | 53.8 ± 27.3 | <0.001 |
| **Arousal index (episodes/h)**                        | 373.25 ± 2.2| 18.0 ± 13.5| 22.6 ± 12.2     | 28.0 ± 12.7    | 54.5 ± 25.0 | <0.001 |
| **SpO₂<90% (min)**                                    | 58.1 ± 101.6| 190 ± 81.0  | 15.0 ± 58.8     | 270 ± 73.1     | 103.1 ± 113.3 | <0.001 |
| **Lowest SpO₂ (%)**                                   | 77.4 ± 15.8| 89.4 ± 5.8   | 86.1 ± 5.8      | 81.3 ± 9.5     | 67.7 ± 17.1 | <0.001 |

*OSA – obstructive sleep apnea; BMI – body mass index; CAD – coronary artery disease; MI – myocardial infarction; ACEI – inhibitors of angiotensin-converting enzyme; NREM – non-rapid eye movement sleep; S1 NREM – stage 1 NREM sleep; S2 NREM – stage 2 NREM sleep; SWS – slow wave sleep; REM – rapid eye movement sleep; AHI – apnea/hypopnea index; ODI – oxygen desaturation index; SpO₂ – arterial oxygen saturation measured by pulse oximetry.

†Data are presented as number (n) and percentage (%) or mean ± standard deviation, unless otherwise stated. \( P \)-values were calculated using one way ANOVA and \( \chi^2 \) test as appropriate.
A total of 202 patients had no OSA, 250 had mild OSA, 186 had moderate OSA, and 541 had severe OSA. Basic demographic data are shown in Table 2. The severity of OSA was significantly associated with male sex, older age, BMI, increasing prevalence of arterial hypertension as reported in personal history, type 2 diabetes, cardiovascular and cerebrovascular morbidity, and the use of antihypertensive drugs. All genotypes were evenly distributed among all OSA severity categories ($P$ value >0.05 for each respective genotype).

**Association of OSA with blood pressure**

Morning and evening SBP and DBP increased with increasing OSA severity, with the highest values in patients with severe OSA (Table 3). Morning SBP and DBP were positively correlated with AHI ($R = 0.212$ and $R = 0.210$, respectively), arousal index ($R = 0.200$ and $R = 0.191$, respectively), desaturation index ($R = 0.239$ and $R = 0.216$, respectively), and the use of antihypertensive drugs. All genotypes were evenly distributed among all OSA severity categories ($P$ value >0.05 for each respective genotype).

**TABLE 3. Blood pressure values in participants grouped by severity of obstructive sleep apnea (OSA)**

| Participants (n)                  | No OSA       | Mild OSA      | Moderate OSA | Severe OSA  |
|----------------------------------|--------------|---------------|---------------|-------------|
| Morning systolic blood pressure (mmHg) | 126.7 ± 19.1 | 126.4 ± 16.7  | 130.2 ± 17.3  | 135.5 ± 18.5 |
| Morning diastolic blood pressure (mmHg) | 81.7 ± 11.5  | 82.7 ± 10.3   | 83.6 ± 10.0   | 87.1 ± 10.9  |
| Evening systolic blood pressure (mmHg) | 128.7 ± 16.3 | 131.8 ± 16.3  | 132.5 ± 18.1  | 136.5 ± 18.3  |
| Evening diastolic blood pressure (mmHg) | 83.3 ± 9.2   | 84.9 ± 8.8    | 85.0 ± 10.3   | 86.6 ± 10.2   |

*Data are presented as mean ± standard deviation, unless otherwise stated. $P$-values were calculated using one way ANOVA.

$P$-value <0.05 vs no OSA.

$P$-value <0.05 vs mild OSA.

$P$-value <0.05 vs moderate OSA.

**TABLE 4. Basic demographic characteristics in participants grouped by JAG1 genotype**

| JAG1 polymorphism genotype | AA          | AG+GG        | $P$   |
|----------------------------|-------------|--------------|-------|
| Participants (n)           | 360         | 819          |       |
| Male sex                   | 252 (70)    | 569 (69)     | 0.911 |
| Age (years)                | 52.5 ± 10.6 | 51.8 ± 11.7  | 0.420 |
| BMI (kg/m²)                | 32.4 ± 6.7  | 32.5 ± 6.5   | 0.581 |
| Antihypertensive medication users | 207 (58) | 473 (58) | 0.965 |
| AHI (episodes/h)           | 34.2 ± 31.6 | 34.6 ± 30.6  | 0.719 |
| ODI (episodes/h)           | 29.2 ± 31.2 | 29.7 ± 29.4  | 0.424 |
| No OSA                     | 61 (17)     | 141 (17)     |       |
| Mild OSA                   | 82 (23)     | 168 (21)     | 0.358 |
| Moderate OSA               | 64 (18)     | 122 (15)     |       |
| Severe OSA                 | 153 (42)    | 388 (47)     |       |

*Data are presented as number (n) and percentage (%) or mean ± standard deviation, unless otherwise stated. BMI = body mass index; AHI = apnea-hypopnea index; ODI = oxygen desaturation index; OSA = obstructive sleep apnea.

**TABLE 5. Blood pressure across obstructive sleep apnea severity groups in AA homozygotes and G allele carriers of the JAG1 gene polymorphism**

| JAG1 polymorphism genotype | No OSA       | Mild OSA      | Moderate OSA | Severe OSA  |
|----------------------------|--------------|---------------|---------------|-------------|
| Morning SBP                | AA           | AG+GG         | $P$           |
| AA                         | 123.4 ± 13.8 | 123.9 ± 16.5  | 127.8 ± 17.5  | 134.7 ± 18.8 |
| AG+GG                      | 128.1 ± 20.9 | 127.6 ± 16.7  | 131.5 ± 17.1  | 135.9 ± 18.3 |
| Morning DBP                | AA           | AG+GG         | $P$           |
| AA                         | 79.2 ± 8.9   | 81.5 ± 9.6    | 82.1 ± 9.6    | 86.5 ± 10.8 |
| AG+GG                      | 82.7 ± 12.3  | 83.2 ± 10.6   | 84.3 ± 10.1   | 87.4 ± 11.0 |
| Evening SBP                | AA           | AG+GG         | $P$           |
| AA                         | 125.5 ± 12.7 | 130.3 ± 15.6  | 132.2 ± 20.2  | 135.2 ± 17.3 |
| AG+GG                      | 130.1 ± 17.5 | 132.6 ± 16.7  | 137.0 ± 18.7  | 0.001       |
| Evening DBP                | AA           | AG+GG         | $P$           |
| AA                         | 82.6 ± 8.7   | 84.1 ± 8.5    | 84.5 ± 10.6   | 85.0 ± 9.9  |
| AG+GG                      | 83.6 ± 9.4   | 85.3 ± 8.9    | 85.3 ± 10.2   | 87.2 ± 10.3 |

*OSA = obstructive sleep apnea; SBP = systolic blood pressure; DBP = diastolic blood pressure.

$P$-value <0.05 vs no OSA.

$P$-value <0.05 vs mild OSA.
tively), and time spent in saturation under 90% ($R = 0.182$ and $R = 0.158$, respectively), with $P < 0.001$ for all. Evening SBP and DBP were positively correlated with AHI ($R = 0.171$ and $R = 0.129$, respectively), arousal index ($R = 0.138$ and $R = 0.107$, respectively), and desaturation index ($R = 0.186$ and $R = 0.145$, respectively), with $P < 0.001$ for all, and evening SBP was correlated with time in desaturation under 90% ($R = 0.094$, $P = 0.002$).

**Association of selected genotypes with blood pressure**

Significant differences in SBP and DBP were observed between the genotype groups of polymorphism in the *JAG1* gene. Alleles A and G of *JAG1* gene polymorphism were distributed according to Hardy-Weinberg equilibrium. Sex distribution, age, BMI, AHI, ODI, antihypertensive medication use, and the proportion of patients according to OSA severity were similar in the two *JAG1* genotype groups (Table 4).

*JAG1* polymorphism genotypes were associated with blood pressure in the entire cohort (Figure 1). After applying the Bonferroni correction for 4 genotyped SNPs, allele G carriers (pooled homozygotes GG and heterozygotes AG) had significantly higher morning SBP ($132.2 \pm 18.6$ vs $129.1 \pm 17.9$ mm Hg, $P = 0.009$), morning DBP ($85.3 \pm 11.2$ vs $82.1 \pm 10.4$ mm Hg, $P = 0.026$), and evening SBP ($129.1 \pm 17.9$ vs $126.2 \pm 16.8$ mm Hg, $P = 0.009$), and even night DBP ($82.1 \pm 10.4$ vs $79.3 \pm 10.0$ mm Hg, $P = 0.026$).

![Graph showing systolic blood pressure](image1)

![Graph showing diastolic blood pressure](image2)

**Figure 1.** Comparison of the systolic and diastolic blood pressure between AA homozygotes and G allele carriers of *JAG1* gene polymorphism; *P*-value <0.0125 vs AA homozygotes. White – AA; gray – AG+GG.
83.3 ± 10.4 mm Hg, \( P = 0.004 \), and evening DBP (85.9 ± 9.9 vs 84.3 ± 9.5 mm Hg, \( P = 0.012 \)) than allele A homozygotes.

We also examined the association of OSA severity with blood pressure in the distinct \( JAG1 \) polymorphism genotype groups. G allele carriers with severe OSA had significantly higher morning and evening SBP and DBP (\( P < 0.05 \) for all) than G allele carriers with no OSA. In addition, AA homozygotes with severe OSA had higher morning SBP and DBP (\( P < 0.05 \) for both), and evening SBP (\( P < 0.05 \)) compared with AA homozygotes with no OSA (Table 5).

To further investigate the association of both intermittent hypoxia and \( JAG1 \) genotype with blood pressure control, we performed multivariate analyses using multiple linear regression models with each respective blood pressure value as a dependent variable and age, sex, BMI, use of antihypertensive medication, ODI, and \( JAG1 \) genotype as independent variables. Both ODI and \( JAG1 \) genotype were significant and independent predictors of morning and evening SBP and DBP (\( P < 0.05 \) for both, Table 6). Introducing AHI instead of ODI as an index of OSA severity in multivariate linear models yielded similar results (data not shown). Finally, we also analyzed a potential independent association of an interaction term \( JAG1 \) genotype*ODI with blood pressure by adding the interaction term to the previous models. Nevertheless, the \( JAG1 \) genotype*ODI interaction term was not a significant predictor of either SBP or DBP in any of the models.

No significant associations between the further three tested SNPs (\( SH2B3, GUCY1A3-GUCY1B3, \) and \( NPR3c5orf23 \)) and blood pressure were observed (Table 7).

**DISCUSSION**

The present genetic association study revealed that among patients with suspected OSA, carriers of the risky G allele of the rs1327235 polymorphism of \( JAG1 \) gene had significantly higher morning SBP and DBP, and evening SBP than AA homozygotes. The association of \( JAG1 \) genotype with blood pressure was independent of age, sex, BMI, and use of antihypertensive medication. Moreover, our data indicate that OSA severity has deleterious effects on blood pressure independently of the effect carried by the \( JAG1 \) genotype. Previously, several GWASs reported links between \( JAG1 \) genotype and increased SBP and DBP, and higher odds of hypertension and coronary artery disease in the general population (5,13). In individuals of European descent, effect size estimate of coded allele G

---

**TABLE 6. Multivariate models with systolic and diastolic blood pressure as dependent variables**

|                      | morning SBP | evening SBP | morning DBP | evening DBP |
|----------------------|-------------|-------------|-------------|-------------|
|                      | \( \beta \) | standard error | \( P \) | \( \beta \) | standard error | \( P \) | \( \beta \) | standard error | \( P \) | \( \beta \) | standard error | \( P \) |
| Age                  | 0.348       | 0.050       | <0.001      | 0.191       | 0.051       | <0.001      | 0.089       | 0.031       | 0.004      | 0.032       | 0.029       | 0.277       |
| Sex                  | -0.458      | 1.122       | 0.683       | -0.757      | 1.156       | 0.513       | -1.510      | 0.697       | 0.031      | -1.726      | 0.664       | 0.009       |
| Body mass index      | 0.348       | 0.098       | <0.001      | 0.238       | 0.100       | 0.017       | 0.152       | 0.061       | 0.013      | 0.072       | 0.057       | 0.208       |
| Antihypertensive use | 4.671       | 1.200       | <0.001      | 5.031       | 1.223       | <0.001      | 1.895       | 0.746       | 0.011      | 1.080       | 0.702       | 0.124       |
| Oxygen desaturation index | 0.068 | 0.021 | 0.001 | 0.051 | 0.021 | 0.19 | 0.045 | 0.013 | <0.001 | 0.029 | 0.012 | 0.018 |
| \( JAG1 \) genotype | 3.211       | 1.085       | 0.003       | 2.201       | 1.113       | 0.048       | 1.884       | 0.674       | 0.005      | 1.512       | 0.639       | 0.018       |

*\( P \)-value for each variable in the model presented. Model for morning systolic blood pressure \( R^2 = 0.16; F = 37.5, P < 0.001 \); model for evening systolic blood pressure \( R^2 = 0.10; F = 19.0, P < 0.001 \); model for morning diastolic blood pressure \( R^2 = 0.08, F = 17.6, P < 0.001 \); model for evening diastolic blood pressure \( R^2 = 0.04, F = 7.1, P < 0.001 \).

**TABLE 7. Associations between single-nucleotide polymorphisms \( SH2B3, GUCY1A3-GUCY1B3, \) and \( NPR3c5orf23 \) and blood pressure**

| Single-nucleotide polymorphism | Risky/non-risky allele (participant) | morning SBP | morning DBP | evening SBP | evening DBP |
|-------------------------------|-------------------------------------|-------------|-------------|-------------|-------------|
| \( SH2B3 \)                   | CC (268)/CT+TT (911)                | 0.414       | 0.734       | 0.801       | 0.207       |
| \( GUCY1A-GUCY1B \)           | AA (93)/AC+CC (1086)                | 0.322       | 0.172       | 0.679       | 0.292       |
| \( NPR3c5orf23 \)             | AA (199)/AG+GG (980)                | 0.362       | 0.791       | 0.088       | 0.076       |

*SBP – systolic blood pressure; DBP – diastolic blood pressure.

**\( P \)-value for comparisons of the respective blood pressures between the two genotype groups for each single-nucleotide polymorphism is presented.**
pertension is independent of confounders such as obesity, smoking, or alcohol intake (15). Increasing severity of sleep apnea is proportional to the increase in blood pressure and incidence of hypertension (15). Moreover, OSA has been identified as a prevalent underlying condition in drug-resistant hypertension (2,16). An important mediator for systemic hypertension in patients with OSA is chronic intermittent hypoxia (15). This type of hypoxia contributes to additional factors related to increases in blood pressure: sympathetic activation, blunted baroreflex sensitivity (17), increased chemosensory activity of the carotid body (18), and endothelial dysfunction (19).

In the studied cohort, the differences in blood pressures between the JAG1 genotype groups were 2.0–4.5 mm Hg for SBP and 0.9–3.5 mm Hg for DBP across different OSA severity groups. Interestingly, in a GWAS, the mean estimated effect size of singular polymorphism was 0.5 mm Hg for DBP and 1.0 mm Hg for SBP (5). Therefore, the differences observed in our study exceeded the average of the expected effect size for a singular polymorphism. On the other hand, differences in blood pressures attributed to a singular gene polymorphism in our and other studies (5) are lower than the reported effect size of mutations in familial hypertensive syndromes, which was 10 mm Hg for SBP (4). In the present study, the differences in SBP and DBP between patients with severe OSA and those without OSA were up to 9 and 6 mm Hg, respectively. These results are comparable to those observed by Peppard et al (15) in their landmark prospective study.

Several genetic association studies have reported links between genetic background and arterial hypertension in OSA. Lavie et al (20) reported that OSA patients with haptoglobin phenotype 2-2 had increased susceptibility to hypertension compared with OSA patients with haptoglobin phenotype 2-1. Riha et al (21) demonstrated an association between tumor necrosis factor-alpha polymorphism and OSA severity; nevertheless, no relationship between tumor necrosis factor-alpha polymorphism and hypertension was observed. Considering the crucial role of sympathetic nervous system activation in the OSA-related arterial hypertension, genetic background of β2-adrenergic receptor was also investigated: heterozygosity for the β2-adrenergic receptor was associated with a lower rate of post-myocardial infarction survival in patients with OSA and a high cardiovascular risk profile. However, functionally relevant polymorphisms of β2-adrenergic receptor did not modify blood pressure induced by OSA (22). In another study, β2-adrenergic receptor gene Arg389Arg genotype was associated with an increased prevalence of hypertension in individuals with mild OSA (23). The results on the role of angiotensin-converting enzyme gene insertion/deletion (I/D) polymorphism in blood pressure in patients with OSA yielded conflicting results. While in one study, the D allele of the I/D polymorphism was linked with central obesity but not with OSA or hypertension (24), in another it was associated with hypertension only (25). Interestingly, Patel et al (26) observed a protective effect of D allele against hypertension in severe OSA, and Boström (27) reported a significant interaction between OSA and I/D polymorphism and the prevalence of hypertension in OSA.

Our study was the first to analyze, in patients with OSA, the potential role of polymorphisms originally identified in GWASs as being significant in blood pressure regulation in general population. Therefore, our results on the associations between the JAG1 gene polymorphism and morning and evening SBP and DBP in patients with OSA confirm and extend the previous results on the role of JAG1 genotype in blood pressure control. JAG1 gene is localized on chromosome 20. It codes jagged 1 protein that serves as a ligand for multiple Notch receptors. Notch signaling is an evolutionary conserved short-range intercellular pathway with a role in many essential processes, such as cell fate determination during embryonic development, vascular morphogenesis, angiogenesis, phenotypic switching, and vascular remodeling after injury (28). Recently, JAG1 has been implicated in the pathogenesis of pulmonary arterial hypertension by aggravating pulmonary vascular remodeling both in animal studies (29) and in patients with tetralogy of Fallot and pulmonary stenosis (30). Mechanisms underlying the association between JAG1 genotype and systemic hypertension might parallel those observed in pulmonary hypertension, but experimental data for this hypothesis are lacking. Of note, a human clinical condition with autosomal dominant heritability, termed Alagille syndrome, involves both major
frameshift mutations of JAG1 gene and systemic arterial hypertension (31). Nevertheless, direct pathophysiological links between JAG1 genotype and blood pressure control remain to be elucidated.

The main strength of our study is a distinct cohort of patients who underwent full attended polysomnography, which is a fundamental method in diagnosing sleep-disordered breathing. Nevertheless, several limitations to the current study need to be also acknowledged. First, only a minority of the genetic variants significantly associated with SBP, DBP, and hypertension in GWAS was near a gene with a recognized role in blood pressure control (4). Moreover, the effect size of each individual variant is very small, and even collectively, the 29 variants explain only 1%-2% of SBP and DBP variance (5). This may clarify the lack of associations between blood pressure and three of the four SNPs tested in the present investigation; further studies in much larger cohorts are needed to analyze such potential associations in more detail. Second, although our results suggest a role for the JAG1 gene in blood pressure control in patients with OSA, investigation of the underlying mechanisms of the observed association was beyond the scope of the present study. Therefore, the present results should be considered hypothesis-generating, and further studies are needed to analyze the relationships between the JAG1 gene polymorphism and blood pressure control in OSA in more detail.

In conclusion, the present study suggests that the risky G allele in the JAG1 genotype is associated with higher morning and evening SBP and DBP in patients referred to sleep laboratory for the evaluation of suspected OSA. Large-scale genetic studies are needed to elucidate the impact of susceptibility polymorphisms that contribute to hypertension in such patients.

Funding This work was funded by the Slovak Research and Development Agency under the contract No. APVV-16-0158, and by grants VEGA 1/0863/15 and VEGA 1/0208/16 of the Ministry of Education, Slovakia.

Ethical approval given by the L. Pasteur University Hospital Ethics Committee.

Declaration of authorship all authors conceived and designed the study; IP, VH, LK, IR, and JZ acquired the data; all authors analyzed and interpreted the data; IP, VH, LK, JZ, ITk, RT, and PJ drafted the manuscript; all authors critically revised the manuscript for important intellectual content; all authors agreed to be accountable for all aspects of the work.

Competing interests All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

References
1 Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560-72. Medline:12748199 doi:10.1001/jama.289.19.2560
2 Logan AG, Perlkowski SM, Mente A, Tisler A, Tkacova R, Niromand M, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2001;19:2271-7. Medline:11725173 doi:10.1097/00004872-200112000-00022
3 Young T, Peppard P, Palta M, Hla KM, Finn L, Morgan B, et al. Population-based study of sleep-disordered breathing as a risk factor for hypertension. Arch Intern Med. 1997;157:1746-52. Medline:9250236 doi:10.1001/archinte.1997.00440360178019
4 Ehret GB, Caulfield MJ. Genes for blood pressure: an opportunity to understand hypertension. Eur Heart J. 2013;34:951-61. Medline:23303660 doi:10.1038/eurheartj.2013.1135
5 Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103-9. Medline:21909115 doi:10.1038/nature10405
6 Waken RJ, de Las Fuentes L, Rao DC. A review of the genetics of hypertension with a focus on gene-environment interactions. Curr Hypertens Rep. 2017;19:23. Medline:28283927 doi:10.1007/s11906-017-0718-1
7 Lieb W, Jansen H, Loley C, Pencina MJ, Nelson CP, Newton-Cheh C, et al. CARDIoGRAM. Genetic predisposition to higher blood pressure increases coronary artery disease risk. Hypertension. 2013;61:995-1001. Medline:23478099 doi:10.1161/HYPERTENSIONAHA.111.00275
8 Berry RB, Budhiraja R, Gottlieb DJ, Gozal D, Iber C, Kapur VK, et al. American Academy of Sleep Medicine. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med. 2012;8:597-619. Medline:23066376
9 American Academy of Sleep Medicine Task Force. Sleep-related breathing disorders in adults: Recommendations for syndrome definition and measurement techniques in clinical research. Sleep. 1999;22:667-89. Medline:10450601 doi:10.1093/sleep/22.5.667
10 Huang Z, Liu Z, Luo Q, Zhao Q, Zhao Z, Ma X, et al. Predictors of blood pressure fall with continuous positive airway pressure treatment in hypertension with coronary artery disease and obstructive sleep apnea. Can J Cardiol. 2015;31:853-9. Medline:25660149 doi:10.1016/j.cjca.2014.09.015
11 Yates A, Akanni W, Amode MR, Barrett D, Bills K, Carvalho-Silva
12 Rodriguez S, Gaunt TR, Day IN. Hardy-Weinberg equilibrium testing of biological ascertainment for mendelian randomization studies. Am J Epidemiol. 2009;169:505-14. medline:1912586 doi:10.1093/aje/kwq359

13 Wain LV, Verwoert GC, O'Reilly PF, Shi G, Johnson T, Johnson AD, et al. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet. 2011;43:1005-11. medline:21909110 doi:10.1038/ng.922

14 Worsnop CJ, naughton mT, Barter Ce, morgan To, anderson aI, Pierce RJ. The prevalence of obstructive sleep apnea in hypertensives. am J Respir Crit Care med. 1998;157:111-5. medline:9445287 doi:10.1164/ajrccm.157.1.9609063

15 Peppard Pe, Young T, Palta m, skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000;342:1378-84. medline:10805822 doi:10.1056/nejm200005113421901

16 Logan aG, Tkacova R, Perlikowski sm, Leung Rs, Tisler a, Floras Js, et al. Refractory hypertension and sleep apnoea: effect of CPAP on blood pressure and baroreflex. Eur Respir J. 2003;21:241-7. medline:12608436 doi:10.1183/09031936.03.0035402

17 Carlson JT, Hedner Ja, sellgren J, elam m, Wallin BG. Depressed baroreflex sensitivity in patients with obstructive sleep apnea. Am J Respir Crit Care Med. 1996;154:1490-6. medline:8912770

18 Iturriaga R, andrade dC, del Rio R. Enhanced carotid body chemosensory activity and the cardiovascular alterations induced by intermittent hypoxia. Front Physiol. 2014;5:468. medline:25520668 doi:10.3389/fphys.2014.00468

19 Patt BT, Jarjoura d, Haddad DN, Sen CK, Roy s, Flavahan NA, et al. Endothelial dysfunction in the microcirculation of patients with obstructive sleep apnea. Am J Respir Crit Care Med. 2010;182:1540-5. medline:2066942 doi:10.1164/rcrm.201002-0162OC

20 Lavi e, Lotan R, Hochberg I, Herer P, Lavie P, Levy AP. Haptoglobin polymorphism is a risk factor for cardiovascular disease in patients with obstructive sleep apnea syndrome. Sleep. 2003;26:592-5. medline:12938813 doi:10.1093/sleep/26.5.592

21 Riha RL, Brander P, Vennelle M, McArdle N, Kerr SM, Anderson NH, et al. Tumour necrosis factor-alpha (-308) gene polymorphism in obstructive sleep apnoea-hypopnoea syndrome. Eur Respir J. 2005;26:673-8. medline:16204600 doi:10.1183/09031936.05.00130804

22 Bartels NK, Börgel J, Wieczorek S, Büchner N, Hanefeld C, Bulut D, et al. Risk factors and myocardial infarction in patients with obstructive sleep apnea: impact of beta2-adrenergic receptor polymorphisms. BMC Med. 2007;5:1. medline:17198546 doi:10.1186/1741-7015-5-1

23 Bengtsson Boström K, Hedner J, Grote L, Melander O, von Wowern F, Rístam L, et al. Polymorphisms in α- and β-adrenergic receptor genes, hypertension, and obstructive sleep apnea: The Skaraborg Sleep Study. Int J Hypertens. 2010;26:458-460. medline:20948559 doi:10.1159/000334079

24 Zhang J, Zhao B, Gesongluobu, Sun Y, Wu Y, Pei W, et al. Angiotensin-converting enzyme gene insertion/deletion (I/D) polymorphism in hypertensive patients with different degrees of obstructive sleep apnea. Hypertens Res. 2000;23:407-11. medline:11016793 doi:10.1291/hypres.23.407

25 Lin L, Finn L, Zhang J, Young T, Mignot E. Angiotensin-converting enzyme, sleep-disordered breathing, and hypertension. Am J Respir Crit Care Med. 2004;170:1349-53. medline:15447944 doi:10.1164/rccm.200405-6160C

26 Patel SR, Larkin EK, Mignot E, Lin L, Redline S. The association of angiotensin converting enzyme (ACE) polymorphisms with sleep apnea and hypertension. Sleep. 2007;30:531-3. medline:17520798 doi:10.1093/sleep/30.4.531

27 Boström KB, Hedner J, Melander O, Grote L, Gullberg B, Rístam LO, et al. Interaction between the angiotensin-converting enzyme gene insertion/deletion polymorphism and obstructive sleep apnoea as a mechanism for hypertension. J Hypertens. 2007;25:779-83. medline:17351369 doi:10.1097/HJH.0b013e328017f6d5

28 Kopan R, Ilagan mX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009;137:216-33. medline:19379690 doi:10.1016/j.cell.2009.03.045

29 Guo Q, Xu H, Yang X, Zhao D, Liu S, Sun X, et al. Notch activation of Ca2+-sensing receptor mediates hypoxia-induced pulmonary hypertension. Hypertens Res. 2017;40:117-29. medline:27581537 doi:10.1080/hr.2016.118

30 Grochowski CM, Loomes KM, Spinner NB. Jagged1 (JAG1): Structure, expression, and disease associations. Gene. 2016;576:381-4. medline:26548814 doi:10.1016/j.gene.2015.10.065

31 Uberos J, Moreno L, Muñoz-Hoyos A. Hypertension and biliary ductopenia in a patient with duplication of exon 6 of the JAG1 gene. Clin Med Insights Pediatr. 2012;6:61-6. medline:23641167 doi:10.4137/CMPed.s9621